Clinical trial
A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation
NCT01174160 is registered in ClinicalTrials.gov with Advanz Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation
- Lead sponsor
- Advanz Pharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2010
- Completion date
- October 31, 2012
- Enrollment
- 123 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.